Once established that Vav1 modulates the activation of Akt1 in breast tumor‐derived cells, we investigated the association between the Vav1/p‐Akt (Ser473) levels and the clinical outcome of breast cancer patients. This evidence concerns the gene AKT1 and breast carcinoma.